Medtronic said fourth quarter worldwide revenue was $8.927 billion, an increase of 3.9% as reported and 5.4% on an organic basis, and full-year revenue was $33.537 billion, an increase of 3.6% as reported and 4.9% on an organic basis.

1. 01

   Medtronic said fourth quarter worldwide revenue was $8.927 billion, an increase of 3.9% as reported and 5.4% on an organic basis, and full-year revenue was $33.537 billion, an increase of 3.6% as reported and 4.9% on an organic basis.

2. 02

   The company said full-year GAAP net income and diluted EPS were $4.662 billion and $3.61, respectively, increases of 27% and 31%, respectively, and non-GAAP net income and diluted EPS were $7.079 billion and $5.49, respectively, increases of 2% and 6%, respectively.

3. 03

   Medtronic said FY25 cash from operations was $7.044 billion, an increase of 4%, and free cash flow was $5.185 billion, unchanged from the prior year, representing free cash flow conversion from non-GAAP net earnings of 73%.

4. 04

   The company said it intends to separate its Diabetes business into a new standalone public company, with completion expected within 18 months. It also provided FY26 organic revenue growth guidance of approximately 5% and non-GAAP diluted EPS guidance of $5.50 to $5.60, including the potential impact from tariffs.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.